Rapamycin allosterically inhibits the proteasome

Molecular Pharmacology

Volumn 84, Issue 1, 2013, Pages 104-113

  Osmulski, Pawel A ^a   Gaczynska, Maria ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEASOME; RAPAMYCIN;

ALLOSTERISM; ARTICLE; CATALYSIS; DRUG CONFORMATION; DRUG TARGETING; DYNAMICS; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL;

ALLOSTERIC REGULATION; CATALYTIC DOMAIN; HUMANS; PEPTIDE HYDROLASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEIN BINDING; PROTEIN CONFORMATION; SIROLIMUS; TOR SERINE-THREONINE KINASES; UBIQUITIN;

EID: 84879105829     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.083873     Document Type: Article

References (37)

1. Adams J (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4:349-360.
2. Bajorek M, Finley D, and Glickman MH (2003) Proteasome disassembly and downregulation is correlated with viability during stationary phase. Curr Biol 13: 1140-1144.
3. Banaszynski LA, Liu CW, and Wandless TJ (2005) Characterization of the FKBP. rapamycin.FRB ternary complex. J Am Chem Soc 127:4715-4721.
4. Cai P, Tsao R, and Ruppen ME (2007) In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites. Drug Metab Dispos 35: 1554-1563.
5. Ciechanover A (2012) Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Biochim Biophys Acta 1824:3-13.
6. Dick LR and Fleming PE (2010) Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 15:243-249.
7. Dowling RJO, Pollak M, and Sonenberg N (2009) Current status and challenges associated with targeting mTOR for cancer therapy. BioDrugs 23:77-91.
8. da Fonseca PC, He J, and Morris EP (2012) Molecular model of the human 26S proteasome. Mol Cell 46:54-66.
9. Gaczynska M and Osmulski PA (2005) Small-molecule inhibitors of proteasome activity. Methods Mol Biol 301:3-22.
10. Gaczynska M and Osmulski PA (2011) Atomic force microscopy of proteasome assemblies. Methods Mol Biol 736:117-132.
11. Gaczynska M, Osmulski PA, Gao Y, Post MJ, and Simons M (2003) Proline-And arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. Biochemistry 42:8663-8670.
12. Gao Y, Lecker S, Post MJ, Hietaranta AJ, Li J, Volk R, Li M, Sato K, Saluja AK, and Steer ML, et al. (2000) Inhibition of ubiquitin-proteasome pathway-mediated I k B a degradation by a naturally occurring antibacterial peptide. J Clin Invest 106: 439-448
13. Goodey NM and Benkovic SJ (2008) Allosteric regulation and catalysis emerge via a common route. Nat Chem Biol 4:474-482.
14. Groll M, Ditzel L, Löwe J, Stock D, Bochtler M, Bartunik HD, and Huber R (1997) Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386:463-471.
15. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, and Carter CS, et al. (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460:392-395.
16. Huber EM and Groll M (2012) The 19S cap puzzle: a new jigsaw piece. Structure 20: 387-388
17. Iwanczyk J, Sadre-Bazzaz K, Ferrell K, Kondrashkina E, Formosa T, Hill CP, and Ortega J (2006) Structure of the Blm10-20 S proteasome complex by cryoelectron microscopy. Insights into the mechanism of activation of mature yeast proteasomes. J Mol Biol 363:648-659.
18. Jankowska E, Gaczynska M, Osmulski P, Sikorska E, Rostankowski R, Madabhushi S, Tokmina-Lukaszewska M, and Kasprzykowski F (2010) Potential allosteric modulators of the proteasome activity. Biopolymers 93:481-495.
19. Kleijnen MF, Roelofs J, Park S, Hathaway NA, Glickman M, King RW, and Finley D (2007) Stability of the proteasome can be regulated allosterically through engagement of its proteolytic active sites. Nat Struct Mol Biol 14:1180-1188
20. Lander GC, Estrin E, Matyskiela ME, Bashore C, Nogales E, and Martin A (2012) Complete subunit architecture of the proteasome regulatory particle. Nature 482: 186-191.
21. Lasker K, Förster F, Bohn S, Walzthoeni T, Villa E, Unverdorben P, Beck F, Aebersold R, Sali A, and Baumeister W (2012) Molecular architecture of the 26S proteasome holocomplex determined by an integrative approach. Proc Natl Acad Sci USA 109:1380-1387.
22. Li J, Post M, Volk R, Gao Y, Li M, Metais C, Sato K, Tsai J, Aird W, and Rosenberg RD, et al. (2000) PR39, a peptide regulator of angiogenesis. Nat Med 6:49-55.
23. Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, and Adomat H, et al. (2010) Effect of noncompetitive proteasome inhibition on bortezomib resistance. J Natl Cancer Inst 102:1069-1082.
24. Liang J, Choi J, and Clardy J (1999) Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution. Acta Crystallogr D Biol Crystallogr 55: 736-744.
25. Liu CW, Corboy MJ, DeMartino GN, and Thomas PJ (2003) Endoproteolytic activity of the proteasome. Science 299:408-411.
26. Meyer S, Kohler NG, and Joly A (1997) Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation. FEBS Lett 413:354-358
27. Ortega J, Heymann JB, Kajava AV, Ustrell V, Rechsteiner M, and Steven AC (2005) The axial channel of the 20S proteasome opens upon binding of the PA200 activator. J Mol Biol 346:1221-1227.
28. Osmulski PA and Gaczynska M (2002) Nanoenzymology of the 20S proteasome: proteasomal actions are controlled by the allosteric transition. Biochemistry 41: 7047-7053.
29. Osmulski PA, Hochstrasser M, and Gaczynska M (2009) A tetrahedral transition state at the active sites of the 20S proteasome is coupled to opening of the a-ring channel. Structure 17:1137-1147.
30. Pickering AM, Koop AL, Teoh CY, Ermak G, Grune T, and Davies KJA (2010) The immunoproteasome, the 20S proteasome and the PA28ab proteasome regulator are oxidative-stress-Adaptive proteolytic complexes. Biochem J 432:585-594.
31. Rabl J, Smith DM, Yu Y, Chang S-C, Goldberg AL, and Cheng Y (2008) Mechanism of gate opening in the 20S proteasome by the proteasomal ATPases. Mol Cell 30: 360-368
32. Rechsteiner M and Hill CP (2005) Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol 15:27-33.
33. Smith DM, Kafri G, Cheng Y, Ng D, Walz T, and Goldberg AL (2005) ATP binding to PAN or the 26S ATPases causes association with the 20S proteasome, gate opening, and translocation of unfolded proteins. Mol Cell 20:687-698
34. Tan X, Osmulski PA, and Gaczynska M (2006) Allosteric regulators of the proteasome: potential drugs and a novel approach for drug design. Curr Med Chem 13:155-165.
35. Unno M, Mizushima T, Morimoto Y, Tomisugi Y, Tanaka K, Yasuoka N, and Tsukihara T (2002) Structure determination of the constitutive 20S proteasome from bovine liver at 2.75 A resolution. J Biochem 131:171-173.
36. Vignot S, Faivre S, Aguirre D, and Raymond E (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16:525-537.
37. Whitby FG, Masters EI, Kramer L, Knowlton JR, Yao Y, Wang CC, and Hill CP (2000) Structural basis for the activation of 20S proteasomes by 11S regulators. Nature 408:115-120.